Gene/Protein Disease Symptom Drug Enzyme Compound
Pivot Concepts:   Target Concepts:
Query: UMLS:C0018801 (heart failure)
 72,216 document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)

An angiotensin II receptor antagonist, candesartan has been shown to improve left ventricular dysfunction and exercise tolerance. The assessment of response to candesartan heart failure in Japan(ARCH-J) is a randomized, double-blind, placebo-controlled 6-month study enrolled 305 patients who has not been previously treated with ACE inhibitors, who had not been adequately controlled with ACE inhibitors or who were intolerant of ACE inhibitors. The incidence of confirmed progression of heart failure was significantly lower in the candesartan group(7.4%) than in the placebo group(22.2%), with risk reduction 63.8. Cardiovascular events were also significantly lower during treatment with candesartan than with placebo(10.8% vs 22.9%) with risk reduction of 50.2%. ARCH-J study showed that candesartan cilexetil, 8 mg/day, significantly improved the progression of heart failure when compared with placebo.
 ...
PMID:[Effect of angiotensin II receptor antagonist on heart failure]. 1473 54

The mortality among patients with heart diseases increases steadily in an aging society like Japan. Among those, the patients with chronic heart failure (CHF) are thought to be increasing rapidly although the official report is missing. It is well-known that BNP or NT-proBNP is useful for a clinical diagnosis of CHF, but a role of the cardiac troponin (cTn) attracts attention as a novel biomarker of their prognosis. However, because the level of cTn in patients with CHF is far lower than that in cases of acute coronary syndrome (ACS), development of the high-sensitive method with precision is desired. In the present study, a new sensitive assay system with an analyzer, ARCHITECT STAT (cTnI hs-ARCH) was basically studied and found more sensitive than other conventional 2 sensitive methods. The performance of cTnI hs-ARCH was evaluated in patients with CHF by comparing it to findings with other 2 methods. When CHF patients are allocated into categories of NYHA classification according to their subjective symptoms, cTnI hs-ARCH was superior to other methods in discriminating subgroups. In addition, multivariable analysis disclosed that cTnI hs-ARCH is influenced by the level of renal function at the minimum among the 3 methods. Therefore, cTnI hs-ARCH may be a useful method for evaluation of prognosis in patients with CHF who often have impaired renal function.
 ...
PMID:[The basic research on the high-sensitive troponin I assay, and the application to evaluation of chronic heart failure]. 2394 74